What is KMDA stock price today?

KMDA (Kamada Ltd) stock is trading at $8.44 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is KMDA stock going up or down today?

KMDA stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy KMDA stock now?

The decision to buy KMDA depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is KMDA a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for KMDA based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is KMDA stock overvalued or undervalued?

KMDA currently trades at a P/E ratio of 24.26 relative to earnings. Our DCF calculator provides intrinsic value estimates to help determine if KMDA is fairly priced.

What is KMDA's P/E ratio?

KMDA has a price-to-earnings (P/E) ratio of 24.26, which measures how much investors are willing to pay per dollar of earnings. Compare this to industry peers and historical averages for context.

What is KMDA's market cap?

KMDA (Kamada Ltd) has a market capitalization of $0.49 billion, making it a small-cap stock.

What is KMDA's price to book ratio?

KMDA trades at a price-to-book (P/B) ratio of 1.82, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does KMDA pay dividends?

Yes, KMDA pays dividends with a current yield of 0.03%. Dividend payments provide income for investors in addition to potential stock price appreciation.

What is KMDA's dividend yield?

KMDA's dividend yield is 0.03%, calculated as annual dividends divided by the current stock price. This represents the annual return from dividends alone.

Is KMDA stock a good long-term investment?

KMDA's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is KMDA's revenue growth rate?

KMDA has shown revenue growth of 0.1% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Yes, KMDA is profitable with a profit margin of 0.1%. This indicates the company generates 0.1 cents of profit for every dollar of revenue.

What are the risks of investing in KMDA?

Key risks for KMDA include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does KMDA compare to its competitors?

Compare KMDA to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize KMDA's performance and positioning.

What is KMDA's stock price target for 2026?

Our AI model provides price targets for KMDA based on fundamental analysis: Bull case $10.97 (+30%), Base case $9.71 (+15%), Bear case $7.60 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about KMDA?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for KMDA. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is KMDA's next earnings report?

KMDA reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

KMDA - Kamada Ltd

NYSE * Health Care * Pharmaceuticals

$8.44

$-0.05 (-0.59%)

About Kamada Ltd

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distributes biopharmaceutical products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for various immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for prevention of hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX to treat hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for salmonella typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; RYPLAZIM for hypoplasminogenemia; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

KMDA Key Statistics

Market Cap

$490.86M

P/E Ratio

24.26

P/B Ratio

1.82

EPS

$0.35

Dividend Yield

0.03%

Revenue Growth

+0.1%

Profit Margin

0.1%

Employees

462

How KMDA Compares to Peers

KMDA has the lowest P/E ratio in Pharmaceuticals, suggesting it may be the most undervalued

KMDA has the highest profit margins in Pharmaceuticals

KMDA has the fastest revenue growth among competitors

P/E Rank

of 2

Margin Rank

of 2

Growth Rank

of 2

Size Rank

of 2

Company	Market Cap	P/E	Growth	Margin	Compare
KMDA(This stock)	$490.86M	24.3	0%	0.1%	-
AMZNAmazon Com	$2.58T	33.4	0%	0.1%	vs AMZN

Kamada Ltd Company Information

Headquarters: Israel
Website: www.kamada.com
Sector: Health Care
Industry: Pharmaceuticals

About Kamada Ltd

KMDA Key Statistics

How KMDA Compares to Peers

Kamada Ltd Company Information

Upcoming Events for KMDA